

UC Davis

UC Davis Electronic Theses and Dissertations

Title

An Investigation of Maternal Energy Demands During Lactation and the Factors Influencing Milk Production

Permalink

<https://escholarship.org/uc/item/8m57j6wn>

Author

Ford, Erin

Publication Date

2022

Peer reviewed|Thesis/dissertation

**An Investigation of Maternal Energy Demands During Lactation
and the Factors Influencing Milk Production**

By

ERIN FORD

THESIS

Submitted in partial satisfaction of the requirements for the degree of

MASTER OF SCIENCE

in

FOOD SCIENCE

in the

OFFICE OF GRADUATE STUDIES

of the

UNIVERSITY OF CALIFORNIA

DAVIS

Approved:

J Bruce German, Chair

Jennifer Smilowitz

Daniela Barile

Committee in Charge

2022

Table of Contents

Acknowledgements	iv
Abstract.....	iv
List of Figures	v
Foreword.....	vi
Helping Mom Help Baby: Nutrition-Based Support for the Mother-Infant Dyad During Lactation	1
Introduction	1
Supporting Lactation Success	2
The Postpartum Mother-Infant Dyad.....	3
The Microbiome of the Mother-Infant Dyad	4
Transfer of Innate and Adaptive Immunity.....	5
Factors That Compromise Postpartum Mother-Infant Interaction	5
Environmental and Physiological Barriers to Breastfeeding	6
Preterm Birth and Congenital Abnormalities that Preclude Breastfeeding.....	7
Maternal Obesity and Breastfeeding.....	8
Nourishing the Mother-Infant Dyad	8
Current Dietary Recommendations.....	8
<i>Belief-Based Food Restrictions During Lactation</i>	10
<i>Toxicological Hazards During Lactation</i>	12
Milk Production as an Indicator of Lactation Success.....	12
<i>Clinical Use of Galactagogues</i>	12
<i>Supporting Postpartum Metabolic Demand</i>	14
Non-Dietary Interventions to Improve Breastfeeding Success.....	14
Conclusion.....	15
References	16

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Preterm Infants

(MOONRISE) Study: Protocol for a Double-Blind Placebo-Controlled Clinical Trial	25
Introduction	25
Methods	26
Study Design	26
<i>Randomization</i>	27
Study Population.....	27
Inclusion/Exclusion Criteria.....	28
<i>Inclusion Criteria</i>	28
<i>Exclusion Criteria</i>	29
Study Supplement	30
Questionnaires.....	30
Daily and Weekly Logs	31
Sample Collection.....	31
<i>24-Hour Milk Volume</i>	31
<i>Expressed Milk Sample</i>	32
<i>Maternal Urine</i>	32
<i>Serum Prolactin</i>	33
Power Analysis	33
Statistical Analysis	33
Data and Specimen Banking	34
Discussion and Conclusion.....	34
References	36

Acknowledgements

I have many to thank for my success on this grand journey. Dr. Bruce German is the man who encouraged me to find something that I love and explore all its possibilities. This served me well in emerging from the halcyon period (as he likes to call it) and creating a project of which I am immensely proud.

Although my time working with Dr. Mark Underwood before he relocated was brief, his kindness and passion for improving the wellbeing of moms and babies did not go unnoticed, and he helped me lay the framework for what would become the entirety of my thesis project. Dr. Kara Riordon-Kuhn took over for his position and I am grateful for her time and her ability to seamlessly transition and become part of the team.

Dr. Jennifer Smilowitz offered her mentorship and extensive experience in coordinating clinical trials. I appreciate her patience over the course of countless drafts and revisions.

I could not be more pleased to leave the future of the MOONRISE Study to Karina Cernioglo, who is an absolutely brilliant mind and works harder than anyone I know.

I am grateful for IBCLCs Katte Smith and Audrey Tullius, who allowed me to shadow them in the UC Davis Medical Center on many occasions and who answered a plethora of questions about breastfeeding.

I appreciate the dedication and guidance of the members of my qualifying exam committee (yes, this was originally intended to be a dissertation). Thank you to Dr. Daniela Barile, as well as Drs. German and Smilowitz, for your flexibility during these past several months as I made the transition from doctoral to master's candidate.

My parents, Robert and Jaime, and my sister Caitlin also deserve special recognition for all the emotional and financial support you provided in my times of greatest need. I know California was often a few thousand miles too far but we made the most of it.

To the twelve people I am honored to call fellow members of the Disgruntled Dozen: Andrea, Andrew, Derrick, Dorie, Jessica, Kay, Ming, Olivia, Sydney, Ted, and Tiffany (plus a few bonus members of the crew including Dan, Reid, Sam, Haruka, and Sushumna)—thank you. The memories in these past few years are going to get me through the rest of this life.

Abstract

Lactation and breastfeeding support the short- and long-term health of both mother and infant, yet the success of these processes depend upon both individual and shared factors. Complications during pregnancy and delivery negatively affect the likelihood that a mother will be capable of breastfeeding for at least the first six months of life, as recommended by the American Academy of Pediatrics (1). Guidelines for women regarding postpartum diet and lifestyle management also fail to reflect the diversity of mother-infant pairs and their circumstances. In our analysis of the literature, we have identified a categorical deficit in modern scientific discourse regarding human lactation; namely, that postpartum involves full-body contribution of resources and thus requires the application of nutrition from a systemic perspective.

These observations, combined with recent research indicating that the vitamin B₃ derivative nicotinamide riboside may improve lactation success while conferring additional long-lasting benefits to the dyad, inspired a randomized-control clinical trial consisting of a small cohort of female participants who have given birth prematurely. As a consequence of the COVID-19 pandemic, recruitment for the described study has been approved by the UC Davis institutional review board but not yet begun at the time of publication. The primary aim is to determine whether supplementation with nicotinamide riboside during the immediate postpartum period has a measurable effect on milk production (i.e. its ability to act as a galactagogue). Secondary outcomes are intended to direct future hypotheses regarding the mechanistic action of this compound (i.e. its ability to act as a metabolic regulator). This contribution to the field of lactation research is significant in that it prioritizes interventions at the beginning of life that demonstrate the potential for measurable improvement in long-term health.

List of Figures

Figure 1. The contributing factors involved in achieving successful lactation are interdependent and unique to each mother-infant pair	2
Figure 2. Procedure for recruitment, screening, and determination of study group.....	26
Figure 3. Activities timeline for the 17-day duration of the MOONRISE study. Symbols represent events denoted in the figure legend	28
Figure 4. Onset of milk production sample entry form.....	31

Foreword

Helping Mom Help Baby: Nutrition-Based Support for the Mother-Infant Dyad During Lactation, was published in *Frontiers in Nutrition* in April of 2020 (doi: 10.3389/fnut.2020.00054). The abstract and figure have been modified to fit the criteria for publication of this thesis.

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Preterm Infants (MOONRISE) Study: Protocol for a Double-Blind Placebo-Controlled Clinical Trial has not been submitted for publication, but documents containing the information presented therewithin have been received and approved by the institutional review board (IRB) at the University of California, Davis. Protocols were developed and authored by Erin Ford in conjunction with Dr. Jennifer Smilowitz, Karina Cernioglo, Dr. Kara Kuhn-Riordon, Dr. Mark Underwood, and Dr. J Bruce German.

Helping Mom Help Baby: Nutrition-Based Support for the Mother-Infant Dyad During Lactation

Erin L. Ford, Mark A. Underwood, and J. Bruce German

Introduction

Breast milk provides a complex, dynamic, and targeted source of nourishment to an infant during the first months of life. Reductionist perspectives of lactation, however, tend to overlook the true diversity of interactions between a mother, her environment, and the growing infant. Each compositional change in breast milk reflects the influence of genetics, environment, health status of the mother, unique developmental needs of the child, and countless additional factors (1–4). Traditionally, lactation research in food science and nutrition has focused on milk’s functionality as the exclusive food for infants. Milk composition is considerably varied. It is distinct between women of different races (5,6), between women of the same race over the course of lactation, and even within a single woman when considering diurnal effects and parity (7–9). Decades of research on the benefits associated with exclusive breastfeeding indicate a direct dose-dependent relationship between human milk consumption and reduced acute conditions in the infant including infection, diarrheal disease, and allergy; and chronic conditions including adult-onset diabetes, hypertension, autoimmunity, and obesity (10–15). A growing body of evidence also supports breastfeeding as a contributor to early structural brain development and consequent neurocognitive advantages (16,17). Less is known about the benefits of lactation for the mother, although improved bone remineralization, more rapid return to pre-pregnancy weight, as well as decreased hypertension, hyperlipidemia, and cardiovascular disease was noted in a metadata analysis of postmenopausal women (18). Industrial development of artificial formula to be used in place of or in conjunction with human breast milk has bolstered a subfield of research primarily concerned with the elucidation of key compositional elements, and from outside milk’s functional context of the mother-infant dyad. In reality, mother and infant operate synergistically. Breastfeeding and lactation remain largely undervalued, as evidenced by their scarcity in published academic literature and the lack of investment within public policy. From a public health perspective, only once the

technologies and principles of scientific investigation address the integrative nourishment of the dyad as a whole can we begin to radically improve health outcomes and quality of life for future generations.




Figure 1. The contributing factors involved in achieving successful lactation are interdependent and unique to each mother-infant pair.

Supporting Lactation Success

Modern precision nutrition has, until recently, been applied almost exclusively to the field of sports performance and the management of chronic diseases in adults. Advances in metabolomics technologies, which detect small metabolites in body fluids, have informed how the interaction between environment, microbiota, and host genetics and epigenetics contribute to the effect of an individual's diet on energy utilization and disease status (19). Still, there exists an enormous need for an approach to nutrition science that emphasizes the achievement of calculable outcomes for a specific stage of life, physiological event (e.g. postpartum and lactation), or environment. Lactation, defined as the collection of innate functions necessary for the provision of adequate milk and coordination between maternal and infant systems, constitutes a key measure of success for the mother-infant dyad and an optimum target for novel

precision medicine strategies. Employing one or more nutritional, social, or therapeutic interventions may be necessary to support lactation success.

Discourse in the fields of food science and nutrition tends to adopt a reductionist perspective aptly branded “nutritionism” by contemporaries in the field, wherein food is considered merely in terms of the sum of its macro- and micronutrient composition. Scholars agree that commercialization of nutrition principles, together with consumer exploitation by the health food industry and popular media, have obfuscated the relationship between diet and health (20,21). Despite an abundance of well-intended claims, there remains a lack of accredited guidelines for achieving long-term wellness in the midst of the modern chronic disease epidemic. By extension, new mothers receive little informed advice regarding how to best nourish themselves and their baby during breastfeeding and beyond.

At present there exist no standardized means of assessing the natural progression of human lactation or defining optimum milk composition; thus, a critical scientific objective centers on the establishment of metrics and reference values for specific infant populations (22). A broad range of maternal and neonatal requirements emerge during the postpartum period. Routine clinical evaluation-- including routine analysis of the health of the dyad, emotional health of the mother, growth of the infant, and assessment of the microbiota and metabolome of the mother-infant pair-- demonstrates the greatest potential for reaping long-term health benefits for the dyad.

The Postpartum Mother-Infant Dyad

The mammary, from a biological and physiological perspective, functions as a specialized bioreactor. Lactation involves all tissues and myriad biological processes of the mother. Under ideal circumstances, lactation also includes cooperation with and feedback from the infant. Meeting the demand of lactation depends upon a critical homeostatic maintenance of energy at the cellular level. This feat that involves efficient recruitment and utilization of essential compounds for communication between mother and infant. It follows that any internal or external perturbation can influence lactation and, consequently, the net success of the mother-infant dyad. Here we propose a more comprehensive view of lactation and breastfeeding through the first years of life.

The Microbiome of the Mother-Infant Dyad

Long-term programming begins in utero. Maternal dietary and environmental exposures influence the fetal immune system, and early communication between a mother, her milk, and the shared microbiota begin to structure processes to come (23). During the first hours to days of life, an infant's gut rapidly acquires ambient bacteria, and it is during this time that dominance is established (24). The recent global focus on health consequences of early microbial colonization has facilitated the realization of several emergent themes. Theme 1: early exposure to *Bifidobacterium longum* subspecies *infantis* in combination with human milk feeding leads to swift colonization and domination of that specific strain within an infant. So long as breastfeeding remains the primary feeding regime, *B. infantis* persists as the keystone bacteria. Theme 2: a dramatic change in composition of the fecal microbiome of the breast-fed infant over the last century is characterized by an increase in fecal pH is associated with decreases in *Bifidobacterium* species and increases in *Enterobacteriaceae* and *Clostrideaceae* (25). In high-resource countries, half of the bacteria colonizing the infant gut are from non-maternal sources in the first four months of life (26). Theme 3: the absence of a single colonizer facilitates an erratic progression of microbes. In spite of exclusive breastfeeding, this ecological community never achieves stability.

Sterile birth—which contrasts starkly with the microbially dense environments of human births prior to the 20th century—has not yet been fully evaluated to determine its evolutionary consequence. Exposure of the neonate to candidate bacterial colonizers directs the trajectory of future microbial composition. In this way, microbiota perturbations that result from initial exposures to the extra-uterine environment can incur lasting effects. Whereas *B. infantis* and other *Bifidobacteria* subspecies historically inhabited the gut of breastfed infants, the former now exists in a remarkably low fraction of babies in developed nations (27,28). A recent comparison of two related subspecies showed more *B. infantis* in samples from infants in rural Indonesia and more *B. longum* subspecies *longum* in samples from infants in urban New Zealand, and that these differences are related to breastfeeding practices (29). *B. infantis* (unlike *B. longum*) has been shown to preferentially consume human milk oligosaccharides and, when provided with this medium, will prevail when inoculated in competition with other bacteria (30). This critical contribution to the immunological integrity of infants supports *B. infantis* as distinctly “milk-oriented”. Further, administration of *B. infantis* to healthy breast-fed term infants eradicates differences in the fecal microbiota due to birth mode while also reducing

levels of fecal Enterobacteriaceae that contain bacterial virulence factors and carry antibiotic resistance genes, resulting in decreased markers of intestinal inflammation (31–33).

Breast milk also facilitates vertical transfer of bacteria from the maternal gut to the neonatal gut, while potentially aiding in the establishment of genus-level dominance (34). Comparison of mother and infant fecal bacterial communities over time reveals a diversity of species and conspecific strains peaking in the first hours following birth and declining in diversity and polymorphic characteristic soon thereafter. Notably, vertical transfer of conspecific strains appears to be the most evolutionarily auspicious form of colonization, as evidenced by the superior retention of maternally derived gut microbes compared to foreign strains (26).

Transfer of Innate and Adaptive Immunity

Immature immune function and abundant bacterial exposure characterize early infancy. Transfer of maternal immunity to her neonate begins in utero with immunoglobulin G through the placenta, as well as maternal antimicrobial proteins and peptides through swallowed amniotic fluid. Short-chain fatty acids produced by gut bacteria contribute to adaptive immunity and the assembly of protective factors that can be exchanged between maternal and infant systems (35). Immunization of the mother is also a safe and effective means of protecting the neonate early in life. Administration rates for influenza and pertussis-- two vaccines currently recommended during pregnancy-- remain low (36). Given this observation in conjunction with the development of several novel vaccines, evidence strongly suggests that vaccination offers a promising intervention for reducing infant mortality (37). Composition of the microbiota and its influence on vaccine response in infants and children demonstrates that breastfeeding continues to assist in immune maturation beyond the neonatal period (38). Transfer of immunity continues after birth with milk components including immunoglobulins, lactoferrin, and lysozyme; thus, breast milk facilitates mother-infant interactions that signal higher order metabolic, neurological, developmental, and immunological processes in the infant (39).

Factors That Compromise Postpartum Mother-Infant Interaction

Designing strategies for a mother and her baby during the critical period immediately following parturition requires consideration of key circumstances, including both the ideal and the conspicuously nonideal. Since breast milk provides

a direct vehicle for transmission of nutrients and bioactive molecules, it is appropriate to first evaluate innate obstacles in its production and provision.

Environmental and Physiological Barriers to Breastfeeding

Of the 80% of mothers who initiate breastfeeding, fewer than 25% maintain through the first six months postpartum, as is recommended by the American Academy of Pediatrics and the World Health Organization (40,41). Failures in meeting these public health recommendations are often multicausal and structurally rooted. For instance, it has been shown that lack of evidence-based educational programs and family support are the top determining factors that govern whether a mother continues to breastfeed beyond hospital discharge (42). Despite a tremendous shift in family dynamics and workforce composition since the beginning of the 21st century, there currently exists no federally mandated minimum for employer-paid maternity or paternity leave in the United States. Many hospitals also routinely provide formula supplements to mothers who have not explicitly expressed a preference to breastfeed, which greatly increases the likelihood of more frequent formula feeding and the corresponding reduction in health benefits associated with exclusive breastfeeding (43). Socioeconomic confounders continue to influence the quality and level of care to which a mother has access. Disproportionate allocation of resources places hardship on financially disadvantaged families.

The decrease in rates of childbirth for women in their teens and twenties occurring coincidentally with an increase in births to women in their thirties and forties has raised the national average for maternal age. As of 2016, the mean age of a mother at the time of the birth of her first child achieved an all-time high of 26.6 years (44). These nationwide trends have introduced a new consideration within the field of lactation and postpartum care; namely, maternal age may influence metabolism and energy investment involved in childbearing and breastfeeding. Parity, which often but not exclusively indicates a history of breastfeeding, also contributes to lactation outcomes. Primiparous mothers generally experience greater difficulty in initiating and maintaining milk supply compared to multiparous mothers during the same period of time and who express a similar intent to breast feed (45). Breastfeeding success is subject to the influence of maternal health status as well. A medical history of mammary damage (augmentative or reductive surgeries, cancer, etc.), birth trauma, and coincident morbidities including diabetes and obesity affect the ability of a

mother to produce and express milk for her baby. Reduction in milk volume and rate of synthesis may be temporary or persist throughout lactation (46–52).

Lactation never operates at 100% efficiency. In this sense, the mother-infant dyad is an inherently imperfect system. The discrepancy between the volume of milk that is synthesized and that which is removed is a unique characteristic of each mother-infant pair, subject to feedback mechanisms that regulate the mammary based on breast fullness as well as physical and hormonal stimulation by the nursing infant (22).

In some cases, the use of pharmaceutical or recreational drugs may contraindicate breastfeeding because of known or potential risk of transfer from the maternal circulation into her milk supply. Generally, compounds of low molecular weight and low protein binding ability; those that remain in high levels in maternal plasma; and those that readily cross the blood brain barrier are prone to mobilization into breast milk (53). Additionally, drugs that alter hormonal regulation of lactation contribute to complications at all stages of breast milk production. Resources such as the Drugs and Lactation database (LactMed®) from the National Library of Medicine and *Hale's Medications & Mother's Milk 2019* (53) provide a comprehensive examination of common substances and the known effects on the mother and infant associated with use during breastfeeding. The diversity of risks documented in the literature pertaining to breast milk contaminants justify support for more rapid, accurate, and sensitive methods for assessing milk composition in a clinical setting. Such analytics would inform conversation between a mother and her care team to advise whether breast milk alternatives might be the appropriate option when cessation of drug use is not possible or desirable.

Preterm Birth and Congenital Abnormalities that Preclude Breastfeeding

Early mother-infant contact is limited when a neonate requires immediate medical attention, as is often the case when infants are born preterm or with congenital anomalies such as diaphragmatic hernia, gastroschisis, intestinal atresia, hypoxic-ischemic encephalopathy, severe forms of cyanotic congenital heart disease, Pierre Robin sequence, and other genetic syndromes. Evidence supporting the benefits of skin-to-skin holding—including dose-dependent improvement in the success of initiating first feed and duration of exclusive breastfeeding—has contributed to increases in rates of breastfeeding at discharge in many hospitals (54–56). Still, the acts of pumping, tube-feeding and feeding at the breast for many infants in the NICU remains arduous. Onset of lactation tends to occur much later in mothers of

preterm infants, with colostrum not becoming available until as late as three days postpartum (57,58). Even when lactogenesis II coincides with parturition (and the subsequent ejection of the placenta), failure to express milk within the first several hours following delivery hours may limit subsequent production (59). Together, these obstacles hinder breastfeeding success and, ultimately, compromise health outcomes for the mother-infant dyad.

Maternal Obesity and Breastfeeding

Multiple studies have demonstrated an association between pre-pregnancy overweight and reduced initiation and maintenance of breastfeeding (60,61). Contributing factors include increased incidence of prolonged labor and caesarean delivery, both of which delay lactogenesis. Ultimately, obese mothers are simultaneously the most likely to benefit from breastfeeding and the least likely to exclusively breastfeed. Research and interventions aimed at reversing this trend remain absent.

Nourishing the Mother-Infant Dyad

The distinct needs of a woman during pregnancy and lactation have prompted regulatory agencies to endorse dietary guidelines for mothers based on prevailing nutritional consensus. These recommendations include warnings for substances that are known to cause harm to a developing fetus or breastfed infant and should therefore be avoided by mothers until cessation of breastfeeding; however, women differ considerably in how they implement dietary changes. Evidence-based advice often competes with popular opinion or culturally rooted practices, which in turn perpetuates misinformation regarding health and nutrition. In creating a more comprehensive approach to nourishment of the mother-infant dyad it is important to consider the resources to which a mother might currently have access.

Current Dietary Recommendations

Diet management for lactating women largely centers on the increased demand for calories and essential nutrients required to sustain production of a sufficient volume of breast milk that is also of high-quality composition. Increasingly, the consequences of unbalanced nutrition to the health of the mother-infant dyad must be evaluated alongside those of undernutrition. A mother expends an average of 500 kcal per day breastfeeding, with greater expenditure during later stages of lactation (62–64). This deficit amounts to a weight loss of one pound per week if the effects of additional dieting or exercise are omitted. On a purely energetic basis, expending 500 kcal per day should rapidly return a mother

to pre-pregnancy weight, though recent evidence suggests that such normalization of body weight and composition is not universal (65). Mobilization of triglycerides alone at this magnitude undoubtedly requires systemic management of metabolic processes. Failure to recruit maternal energy stores for breast milk indicates that additional factors influence whole body fuel metabolism during lactation. Imbalances in these key metabolic signals may contribute to the risk of maternal obesity and explain the observation that mothers who breastfeed lose body fat more rapidly during the postpartum period compared to those who supplement breast milk with formula or other foods. The increase in widespread occurrence of metabolic dysregulation in the general population persists as one of the foremost health-related catastrophes of the 21st century. Lactating mothers likely experience the very same issues, with destructive effects on the progress of lactation and the quality of their milk. Indeed, altering the trajectory of global health for future generations means including lactation recovery as an essential element of postpartum care.

Precision nutrition strategies for lactation have yet to be implemented in public health policy despite their commercial availability elsewhere. Action in this direction would necessitate an understanding of the diversity among lactating women and their nutritional responses as opposed to the circumstances of lactation alone. The United States Department of Agriculture (USDA) currently recommends a modified “MyPlate” approach to maternal nutrition, with the acknowledgement that lactation requires increased intake of certain micronutrients, via multivitamin or diet, in order to reduce the risk of maternal and infant deficiencies (63). The most recent specifications focus on greens and starchy vegetables; fruits with high water and potassium content; fortified cereal grains; low-fat and calcium-rich dairy products; and a variety of plant- or animal-based protein sources while minimizing intake of seafood that tends to contain toxic levels of mercury. Additionally, the USDA advises that women limit added salt and select options that are high in iron, antioxidants, and omega-3 fats. Caffeinated, alcoholic, and sugar-sweetened beverages are suggested to be consumed infrequently (66). In 2018 the Center for Disease Control published updated guidelines emphasizing many of the same principles, referencing the USDA’s “MyPlate” as an appropriate tool for evaluating individual requirements (62). The Children’s Hospital of Philadelphia (CHOP), a leading center in breastfeeding and neonatal care, developed a more generalized plan for mothers to consult when making dietary selections while breastfeeding. This plan emphasizes the importance of variety while assessing how certain foods consumed by the mother may affect the infant on a case-by-case basis (67).

In 2001, the World Health Organization (WHO) published a booklet aimed at educating women about diet during pregnancy and lactation. These recommendations rely heavily on high-fiber carbohydrates as a main source of calories, as was recommended by the USDA until the 21st century revisions that shifted focus to fresh fruits and vegetables. Even then, plant-based foods are recommended above dairy and meat. Animal products are suggested as a supplementary means of acquiring vitamins and minerals that cannot be obtained from plant foods. According to this bulletin, low-fat options are preferred as a means of reducing cardiovascular risk, a precaution rooted in the global approach to eradicating heart disease in a primarily adult male population (68). Furthermore, diagnostics for determining cholesterol and assessing cardiac risk have been ubiquitously available for decades while no such measures have been attempted for routinely analyzing the composition of mother's own milk or the quality of diet as it pertains to lactation outcomes. Given the nature of public dietary targets it is clear that government agencies have not adequately prioritized lactation as warranting unique nutritional guidance. No updated editions from WHO have been made available to the international public.

Despite the global shift away from meat, dairy, and grains as predominant diet components, dieticians and other healthcare professionals remain largely undecided regarding the adequacy of vegetarian or vegan diets for the health of both mother and infant during pregnancy and postpartum. Indeed, poorly planned plant-based diets restrict or eliminate sources of essential vitamins and minerals even while consuming plentiful calories. For lactating women who wish to continue with a lifestyle that omits some or all animal products, carefully monitoring food intake and fortifying with supplements is essential to the success of lactation and overall wellness for the dyad.

Belief-Based Food Restrictions During Lactation

Purposeful omission of certain foods during breastfeeding is a common practice and is often motivated by historical customs, anecdotal claims, or popular media. It is important to distinguish verified dietary restrictions, allergies, or aversions which may or may not have been present before pregnancy from those that are voluntarily imposed. Sensitivities and adverse reactions in a mother or her baby in response to a particular food should always be monitored carefully by a care provider, but avoidance of entire classes of food based on scientifically unfounded or outdated claims may result in suboptimal nutrition, which can negatively affect the mother-infant dyad.

In a 2012 survey of lactation consultants based in the United States, researchers found that approximately 44% were familiar with folklore related to contraindicative foods perpetuated throughout the field, though only a minor percentage passed on this advice to patients (69). Several commonly avoided foods are those believed to promote allergy, colic, and gas in infants. Development of atopy in children has long been associated with the introduction of allergens from the maternal diet into breast milk. Whether or not these allergens result in morbidity has been the subject of controversy. Early introduction to peanuts from the maternal diet while breastfeeding has demonstrated both protective and adverse effects on the development of allergy in infants (70). Okan et al. (70) reported that the mothers of infants with colic tended to consume fewer grapes and lemons compared to the mothers of infants without colic. Furthermore, duration of crying episodes in the infants with colic was positively correlated with total dietary protein and negatively correlated with banana consumption, though both were of weak association and these findings have not been corroborated in the literature. One study noted positive associations between maternal consumption of cruciferous vegetable, cow's milk, onion, and chocolate and colic symptoms in breastfed infants (71). Yet another concluded that avoidance of bovine milk and eggs showed no effect on infant outcomes with regard to allergy prevention or risk (72). Alcohol has historically appeared on both sides of the argument in literature and popular media, with some alcoholic beverages even being marketed toward lactating women as a means of augmenting low milk supply (73). Alternative findings have indicated that moderate alcohol consumption during lactation temporarily inhibits oxytocin production and the consequent reflex ejection of milk from the mammary despite a corresponding increase in prolactin. Together, these physiological effects of endocrine disruption can compromise milk supply (74).

Prelacteal feeding—or the provision of a substance other than mother's milk to a neonate prior to the first breastfeeding—remains a common practice among Islamic and Hindu populations worldwide. In some instances, women may forego colostrum altogether and instead provide nourishment via water, sugar solutions, or herbal mixtures. Particularly within small communities, beliefs about colostrum being unclean or insufficient in volume have persisted (75). Religious convention reinforces long-held beliefs surrounding breast milk and infant nutrition, but in some cases prelacteal feeding and the ideologies regarding first milk can be harmful. Infants who don't receive the immune-fortifying compounds found in colostrum are at an increased risk of acute infection and related morbidities. Women who engage in prelacteal feeding also tend to initiate breastfeeding later. A hospital-based study conducted in

India established a significant association between a delay in initial breastfeed and prelacteal feeding practices. Provision of mother's milk within the first hour postpartum confers the greatest benefit to the newborn, and prelacteal feeding can present an obstruction. Maternal education, birth mode, gestational age, antenatal breastfeeding counseling, and prelacteal feeding were determined to be the most influential factors associated with predicting timely initiation of breastfeeding (76). It is important to consider the sanctity of ceremonial traditions surrounding childbirth in many religions. By providing maternal education and support during the early postpartum period it is possible to advocate for the welfare of a mother and her infant while at the same time respecting the wishes of the family.

Toxicological Hazards During Lactation

As high-level consumers in the food chain, humans risk ingesting environmental substances that may harm an infant through breast milk, not unlike contraindicative drugs discussed previously. Predatory fish are known to bioaccumulate methyl mercury and other persistent organic pollutants, with concentration being directly related to life span, size, adiposity, and predation status of the fish (77). Generally, even low-mercury containing fish are advised to be consumed no more frequently than three times per week. Seafood with the highest tested mercury content such as king mackerel, orange roughy, swordfish, and tilefish are recommended to be avoided entirely by women while breastfeeding (78). Farmed fish and the increasingly prevalent practice of fishmeal feeding appears to exacerbate the aggregation of environmental toxins and increase human exposure (77). Organic mercury is both highly absorbed from maternal diet but also readily transferred into breast milk where it can disrupt cognitive development in infants (53).

Milk Production as an Indicator of Lactation Success

The ultimate objective of lactation is to foster development of the infant while simultaneously supporting longevity and wellness of the mother. Breastfeeding encourages success of the mother-infant dyad, but only if all adaptations facilitate mutual benefit. In many cases it is important to consider ancillary measures when the demands of breastfeeding exceed the capacity of a mother to effectively provide for her infant.

Clinical Use of Galactagogues

Actual or perceived insufficient milk supply is one of the most common reason for terminating exclusive breastfeeding prior to six months postpartum (79,80). Contrary to many women's assumptions, neonates require a

small volume of milk in the first days of life. Considering that an infant's stomach capacity is less than 20 mL at birth, he or she initially requires mere teaspoons per feeding session (81). Still, in the event of delayed onset of lactation or prolonged low milk supply, galactagogues are commonly used in a clinical setting to stimulate milk production. Domperidone and metoclopramide, both of which primarily act to facilitate gastric emptying and relief of indigestion, are prescribed as off-label pharmaceutical galactagogues due to their ability as dopamine antagonists to acutely increase prolactin levels (82,83). Domperidone is currently not approved for use in the United States due to an increased risk of cardiovascular death associated with long-term use, while metoclopramide now carries a black box warning to emphasize the risk of tardive dyskinesia (84). Additionally, both have been noted to negatively impact milk production after cessation of use (53,82).

Botanical galactagogues (classified as such to distinguish them from pharmaceutical counterparts) exist as popular alternatives to traditional medicine, persisting throughout Western medical practice and among breastfeeding support groups despite unsubstantiated clinical evidence of efficacy. These substances are considered dietary supplements and are therefore not regulated for purity and potency by the FDA. Fenugreek is widely available and abundantly utilized globally as a botanical galactagogue. It does not appear to present any risk of acute toxicity (53,85), though its physiological mode of action remains undetermined and the effects of long-term usage have not been evaluated. To date, only anecdotal reports and non-placebo-controlled studies have been published in the literature regarding fenugreek's touted galactagogic capacity. Recommended dosages provided by fenugreek manufacturers typically exceed 6000 milligrams per day, and users often note a characteristic maple syrup scent in sweat and urine. Several case reports have been published describing extensive analysis of infants for maple syrup urine disease ultimately related to maternal fenugreek intake, underscoring the need for a careful history of maternal intake (86,87). Risks associated with peanut allergy have been noted (53). In a small (n=26) convenience-sampled study conducted on the effects of fenugreek supplementation on prolactin levels and milk production in mothers of preterm infants, a dosage of 1725 milligrams daily failed to yield statistically significant changes to either metric (88).

Several peptidic compounds that act as oxytocin receptor agonists have recently demonstrated the potential for use in stimulating milk production, particularly for mothers of premature infants. A recent clinical trial (ongoing at the time of publication) is evaluating the effectiveness of a drug marketed as Merotocin, which selectively binds to a single

oxytocin receptor, reducing the likelihood of acute hyponatremia associated with excess use and preventing collateral endocrine perturbation (89).

Supporting Postpartum Metabolic Demand

Current nutrition strategies applied to lactation primarily center on dietary intervention as a means of increasing the availability of essential nutrients required for milk production in addition to pharmacological support for hormonal stimulation of the mammary. The mammary operates inextricably from the rest of the body; therefore, metabolic insufficiency is expected to directly interfere with lactation success even with an adequate diet and complete biological development. For a variety of reasons, a mother may be metabolically incapable of assembling and transporting the substrates necessary for robust production. An alternative and complementary strategy involves regulation of whole-body metabolism and nourishment of diverse processes for systemic support of lactation.

Physiological, immunological, or metabolic stresses as well as birth method, infectious state, and maternal age all compromise a mother's metabolic performance. The most compelling evidence in support of targeted metabolic interventions for influencing the trajectory of lactation and outcomes of the mother-infant dyad is that of the response to nicotinamide riboside in lactating mice (90). Parturition and lactation demand considerable recruitment from maternal energy stores. Depletion of these stores, which exist in the form of NADH and its structural variants, reduces biomolecule synthesis and mobilization required for routine assembly of milk components. Production and utilization of energy depends upon the efficiency and availability of energy-carrying molecules. In a recent publication by Ear et al., postpartum metabolic stress was modeled in rat dams. Supplementation with nicotinamide riboside, a bioavailable NAD⁺ precursor, improved maternal response to postpartum via maintenance of lean body mass with a corresponding net improvement in volume and qualitative measures of milk consistent with improved maternal nutrient mobilization. Remarkably, the accompanying evidence supports observations of developmental, behavioral, and neurocognitive benefits in the pups that lasted into adulthood (90).

Non-Dietary Interventions to Improve Breastfeeding Success

Limited research supports meditation, yoga, exercise, and improved sleep quality as potential strategies for prevention and treatment of maternal stress, anxiety, and depression (91–97). Available studies suggest that regular

moderate exercise during lactation improves cardiovascular fitness, plasma lipids, and insulin response. Further, exercise as an intervention during the lactation period does not negatively impact milk composition or volume, or maternal bone density (98–100). With the exception of a single proposed trial (101), we were unable to find any conclusive studies investigating the impact of the aforementioned strategies on breastfeeding success.

Conclusion

Lactation-specific conditioning provides a unique opportunity to alter long-term trajectories for both mother and infant. Alleviating chronic disease and morbidity in adulthood requires prioritizing health at the beginning of life, and yet prevailing standards for nutrition remain oversimplified to the point of being largely inapplicable.

Modern research efforts in human health and nutrition have placed near-exclusive emphasis on the benefits of specific foods or their constituent compounds as a panacea for disease. Health claims regarding the benefits of “superfoods” and nutraceuticals often center upon the notion that exogenous nutrients are taken up and seamlessly incorporated to impart a predictable, desired effect. In reality, biological systems are not universally equipped to utilize all currency equally (102). Current research continues to address cellular substrates and co-factors as targets for nutritional intervention strategies, as these directly influence the production and utilization of energy at a fundamental level. If performance output is assessed as a discrete and integrative indicator of total body nutrition, this focal shift would lead a monumental new wave of precision medicine. Ultimately, increasing efficiency would reduce disease and metabolic stress indicators while improving overall success during lactation and beyond.

Optimizing lactation for each mother-infant dyad requires a paradigm shift to dramatically expand research, education, and resources with this goal in mind. At-risk dyads, such as those affected by obesity, diabetes, preterm birth, and congenital anomalies, warrant exceptional dedication to care and demonstrate the greatest capacity for improvement. It is essential that prospective research efforts contribute to the development of new methods and technologies for evaluating nutritional and metabolic status. Furthermore, these advancements should coincide with the adoption of new policy to replace outdated practices and bolster timely accessibility to mother-infant pairs.

References

1. SECTION ON BREASTFEEDING. Breastfeeding and the Use of Human Milk. PEDIATRICS 2012;129:e827–41.
2. Olivares M, Albrecht S, De Palma G, Ferrer MD, Castillejo G, Schols HA, Sanz Y. Human milk composition differs in healthy mothers and mothers with celiac disease. Eur J Nutr 2015;54:119–28.
3. Wacklin P, Mäkivuokko H, Alakulppi N, Nikkilä J, Tenkanen H, Råbinä J, Partanen J, Aranko K, Mättö J. Secretor Genotype (FUT2 gene) Is Strongly Associated with the Composition of Bifidobacteria in the Human Intestine. Otto M, editor. PLoS ONE 2011;6:e20113.
4. Bauer J, Gerstl J. Longitudinal analysis of macronutrients and minerals in human milk produced by mothers of preterm infants. Clinical Nutrition 2011;30:215–20.
5. Powe CE, Knott CD, Conklin-Brittain N. Infant sex predicts breast milk energy content. Am J Hum Biol 2010;22:50–4.
6. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, et al. Human gut microbiome viewed across age and geography. Nature 2012;486:222–7.
7. Yuhas R, Pramuk K, Lien EL. Human milk fatty acid composition from nine countries varies most in DHA. Lipids 2006;41:851–8.
8. Kent JC. Volume and Frequency of Breastfeedings and Fat Content of Breast Milk Throughout the Day. PEDIATRICS 2006;117:e387–95.
9. Lubetzky R, Littner Y, Mimouni FB, Dollberg S, Mandel D. Circadian Variations in Fat Content of Expressed Breast Milk from Mothers of Preterm Infants. Journal of the American College of Nutrition 2006;25:151–4.
10. Bachour P, Yafawi R, Jaber F, Choueiri E, Abdel-Razzak Z. Effects of Smoking, Mother's Age, Body Mass Index, and Parity Number on Lipid, Protein, and Secretory Immunoglobulin A Concentrations of Human Milk. Breastfeeding Medicine 2012;7:179–88.

11. Bode L. Human Milk Oligosaccharides in the Prevention of Necrotizing Enterocolitis: A Journey From in vitro and in vivo Models to Mother-Infant Cohort Studies. *Frontiers in Pediatrics* 2018;6:385.
12. Hair AB, Peluso AM, Hawthorne KM, Perez J, Smith DP, Khan JY, O'Donnell A, Powers RJ, Lee ML, Abrams SA. Beyond Necrotizing Enterocolitis Prevention: Improving Outcomes with an Exclusive Human Milk-Based Diet. *Breastfeeding Medicine* 2016;11:70–4.
13. Quigley MA, Kelly YJ, Sacker A. Breastfeeding and Hospitalization for Diarrheal and Respiratory Infection in the United Kingdom Millennium Cohort Study. *PEDIATRICS* 2007;119:e837–42.
14. Owen CG, Martin RM, Whincup PH, Smith GD, Cook DG. Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. *The American Journal of Clinical Nutrition* 2006;84:1043–54.
15. Harder T, Bergmann R, Kallischnigg G, Plagemann A. Duration of Breastfeeding and Risk of Overweight: A Meta-Analysis. *American Journal of Epidemiology* 2005;162:397–403.
16. Yan J, Liu L, Zhu Y, Huang G, Wang PP. The association between breastfeeding and childhood obesity: a meta-analysis. *BMC Public Health* 2014;14:1267.
17. McCrory C, Murray A. The Effect of Breastfeeding on Neuro-Development in Infancy. *Matern Child Health J* 2013;17:1680–8.
18. Deoni SCL, Dean DC, Piryatinsky I, O'Muircheartaigh J, Waskiewicz N, Lehman K, Han M, Dirks H. Breastfeeding and early white matter development: A cross-sectional study. *NeuroImage* 2013;82:77–86.
19. Schwarz EB, Ray RM, Stuebe AM, Allison MA, Ness RB, Freiberg MS, Cauley JA. Duration of lactation and risk factors for maternal cardiovascular disease. *Obstet Gynecol* 2009;113:974–82.
20. Cesare Marincola F, Dessì A, Corbu S, Reali A, Fanos V. Clinical impact of human breast milk metabolomics. *Clinica Chimica Acta* 2015;451:103–6.
21. Churchill LR, Churchill SC. Buying Health: The Costs of Commercialism and an Alternative Philosophy. *Int J Health Policy Manag* 2013;1:91–3.
22. Barnhill A. Nutritionism, Commercialization and Food Comment on “Buying Health: The Costs of Commercialism and an Alternative Philosophy.” *Int J Health Policy Manag* 2013;1:223–5.

23. Boss M, Gardner H, Hartmann P. Normal Human Lactation: closing the gap. *F1000Res* 2018;7.
24. Gray LEK, O'Hely M, Ranganathan S, Sly PD, Vuillermin P. The Maternal Diet, Gut Bacteria, and Bacterial Metabolites during Pregnancy Influence Offspring Asthma. *Front Immunol* 2017;8:365.
25. Zivkovic AM, Lewis ZT, German JB, Mills DA. Establishment of a Milk-Oriented Microbiota (MOM) in Early Life: How Babies Meet Their MOMs. 2013;5:11.
26. Henrick BM, Hutton AA, Palumbo MC, Casaburi G, Mitchell RD, Underwood MA, Smilowitz JT, Frese SA. Elevated Fecal pH Indicates a Profound Change in the Breastfed Infant Gut Microbiome Due to Reduction of *Bifidobacterium* over the Past Century. *mSphere* 2018;3.
27. Ferretti P, Pasolli E, Tett A, Asnicar F, Gorfer V, Fedi S, Armanini F, Truong DT, Manara S, Zolfo M, et al. Mother-to-Infant Microbial Transmission from Different Body Sites Shapes the Developing Infant Gut Microbiome. *Cell Host Microbe* 2018;24:133-145.e5.
28. Huda MN, Lewis Z, Kalanetra KM, Rashid M, Ahmad SM, Raqib R, Qadri F, Underwood MA, Mills DA, Stephensen CB. Stool Microbiota and Vaccine Responses of Infants. *PEDIATRICS* 2014;134:e362–72.
29. Lewis ZT, Totten SM, Smilowitz JT, Popovic M, Parker E, Lemay DG, Van Tassell ML, Miller MJ, Jin Y-S, German JB, et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. *Microbiome* 2015;3:13.
30. Lawley B, Ota A, Moloney-Geany K, Diana A, Houghton L, Heath A-LM, Taylor RW, Tannock GW. Fecal Microbiotas of Indonesian and New Zealand Children Differ in Complexity and *Bifidobacterium* Taxa during the First Year of Life. *Appl Environ Microbiol* 2019;85.
31. Casaburi G, Duar RM, Vance DP, Mitchell R, Contreras L, Frese SA, Smilowitz JT, Underwood MA. Early-life gut microbiome modulation reduces the abundance of antibiotic-resistant bacteria. *Antimicrob Resist Infect Control* 2019;8:131.
32. Frese SA, Hutton AA, Contreras LN, Shaw CA, Palumbo MC, Casaburi G, Xu G, Davis JCC, Lebrilla CB, Henrick BM, et al. Persistence of Supplemented *Bifidobacterium longum* subsp. *infantis* EVC001 in Breastfed Infants. *mSphere* 2017;2.

33. Casaburi G, Frese SA. Colonization of breastfed infants by *Bifidobacterium longum* subsp. *infantis* EVC001 reduces virulence gene abundance. *Human Microbiome Journal* 2018;9:7–10.
34. Henrick BM, Chew S, Casaburi G, Brown HK, Frese SA, Zhou Y, Underwood MA, Smilowitz JT. Colonization by *B. infantis* EVC001 modulates enteric inflammation in exclusively breastfed infants. *Pediatr Res* 2019;
35. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, Li Y, Xia Y, Xie H, Zhong H, et al. Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell Host & Microbe* 2015;17:690–703.
36. Gonçalves P, Araújo JR, Di Santo JP. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. *Inflammatory Bowel Diseases* 2018;24:558–72.
37. Lindley MC, Kahn KE, Bardenheier BH, D'Angelo DV, Dawood FS, Fink RV, Havers F, Skoff TH. Vital Signs: Burden and Prevention of Influenza and Pertussis Among Pregnant Women and Infants — United States. *MMWR Morb Mortal Wkly Rep* 2019;68:885–92.
38. Madhi SA, Cutland CL, Jose L, Koen A, Govender N, Wittke F, Olugbosi M, Meulen AS, Baker S, Dull PM, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. *The Lancet Infectious Diseases* 2016;16:923–34.
39. Huda MN, Ahmad SM, Alam MJ, Khanam A, Kalanetra KM, Taft DH, Raqib R, Underwood MA, Mills DA, Stephensen CB. *Bifidobacterium* Abundance in Early Infancy and Vaccine Response at 2 Years of Age. *Pediatrics* 2019;143.
40. Indrio F, Martini S, Francavilla R, Corvaglia L, Cristofori F, Mastrolia SA, Neu J, Rautava S, Russo Spena G, Raimondi F, et al. Epigenetic Matters: The Link between Early Nutrition, Microbiome, and Long-term Health Development. *Frontiers in Pediatrics* 2017;5:178.
41. WHO | Exclusive breastfeeding for six months best for babies everywhere [Internet]. WHO. 2011 [cited 2019 Jul 5]. Available from: https://www.who.int/mediacentre/news/statements/2011/breastfeeding_20110115/en/

42. Spatz DL. Using Evidence on Human Milk and Breastfeeding to Transform Care. *Journal of Obstetric, Gynecologic & Neonatal Nursing* 2015;44:409–11.
43. Stuebe A. The risks of not breastfeeding for mothers and infants. *Rev Obstet Gynecol* 2009;2:222–31.
44. National Vital Statistics Reports Volume 67, Number 1, January 31, 2018. 67:55.
45. Hackman NM, Schaefer EW, Beiler JS, Rose CM, Paul IM. Breastfeeding Outcome Comparison by Parity. *Breastfeeding Medicine* 2015;10:156–62.
46. Michalopoulos K. The Effects of Breast Augmentation Surgery on Future Ability to Lactate. *Breast Journal* 2007;13:62–7.
47. Souto GC, Giugliani ERJ, Giugliani C, Schneider MA. The Impact of Breast Reduction Surgery on Breastfeeding Performance. *J Hum Lact* 2003;19:43–9.
48. Beck CT, Watson S. Impact of Birth Trauma on Breast-feeding: A Tale of Two Pathways. *Nursing Research* 2008;57:228–36.
49. Matias SL, Dewey KG, Quesenberry CP, Gunderson EP. Maternal prepregnancy obesity and insulin treatment during pregnancy are independently associated with delayed lactogenesis in women with recent gestational diabetes mellitus. *The American Journal of Clinical Nutrition* 2014;99:115–21.
50. Li R, Jewell S, Grummer-Strawn L. Maternal obesity and breast-feeding practices. :6.
51. Riddle SW, Nommsen-Rivers LA. A Case Control Study of Diabetes During Pregnancy and Low Milk Supply. *Breastfeeding Medicine* 2016;11:80–5.
52. Azim HA, Bellettini G, Gelber S, Peccatori FA. Breast-feeding after breast cancer: if you wish, madam. *Breast Cancer Res Treat* 2009;114:7–12.
53. Hale TW. *Hale's Medications & Mothers' Milk 2019: A Manual of Lactational Pharmacology* [Internet]. New York, UNITED STATES: Springer Publishing Company; 2018 [cited 2019 Jul 5]. Available from: <http://ebookcentral.proquest.com/lib/ucdavis/detail.action?docID=5358944>
54. Aghdas K, Talat K, Sepideh B. Effect of immediate and continuous mother–infant skin-to-skin contact on breastfeeding self-efficacy of primiparous women: A randomised control trial. *Women and Birth* 2014;27:37–40.

55. Bramson L, Lee JW, Moore E, Montgomery S, Neish C, Bahjri K, Melcher CL. Effect of Early Skin-to-Skin Mother—Infant Contact During the First 3 Hours Following Birth on Exclusive Breastfeeding During the Maternity Hospital Stay. *J Hum Lact* 2010;26:130–7.
56. Moore ER, Anderson GC. Randomized Controlled Trial of Very Early Mother-Infant Skin-to-Skin Contact and Breastfeeding Status. *Journal of Midwifery & Women’s Health* 2007;52:116–25.
57. Henderson JJ, Hartmann PE, Newnham JP, Simmer K. Effect of Preterm Birth and Antenatal Corticosteroid Treatment on Lactogenesis II in Women. *PEDIATRICS* 2008;121:e92–100.
58. Hartmann P, Cregan M. Lactogenesis and the effects of insulin-dependent diabetes mellitus and prematurity. *J Nutr* 2001;131:3016S-20S.
59. Spatz DL, Froh EB, Schwarz J, Houg K, Brewster I, Myers C, Prince J, Olkkola M. Pump Early, Pump Often: A Continuous Quality Improvement Project. *J Perinat Educ* 2015;24:160–70.
60. Amir LH, Donath S. A systematic review of maternal obesity and breastfeeding intention, initiation and duration. *BMC Pregnancy Childbirth* 2007;7:9.
61. Visram H, Finkelstein SA, Feig D, Walker M, Yasseen A, Tu X, Keely E. Breastfeeding intention and early post-partum practices among overweight and obese women in Ontario: a selective population-based cohort study. *J Matern Fetal Neonatal Med* 2013;26:611–5.
62. CDC. Diet considerations for breastfeeding mothers. [Internet]. Centers for Disease Control and Prevention. 2018 [cited 2019 Jul 1]. Available from: <https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/diet-and-micronutrients/maternal-diet.html>
63. Nutritional Needs While Breastfeeding [Internet]. Choose MyPlate. 2015 [cited 2019 Jul 1]. Available from: <https://www.choosemyplate.gov/moms-breastfeeding-nutritional-needs>
64. Protecting Infants Through Human Milk Advancing the Scientific Evidence. Springer Verlag; 2011.
65. Olson CM, Strawderman MS, Hinton PS, Pearson TA. Gestational weight gain and postpartum behaviors associated with weight change from early pregnancy to 1 y postpartum. *Int J Obes* 2003;27:117–27.
66. Making Healthy Choices in Each Food Group [Internet]. Choose MyPlate. 2015 [cited 2019 Jul 1]. Available from: <https://www.choosemyplate.gov/moms-making-healthy-food-choices>

67. Philadelphia TCH of. Diet for Breastfeeding Mothers [Internet]. 2014 [cited 2019 Jul 2]. Available from: <https://www.chop.edu/pages/diet-breastfeeding-mothers>
68. Healthy eating during pregnancy and breastfeeding. :26.
69. Schaffir J, Czaplá C. Survey of Lactation Instructors on Folk Traditions in Breastfeeding. *Breastfeeding Medicine* 2012;7:230–3.
70. Aksoy Okan M, Gunduz M, Okur M, Akgun C, Esin K. Does maternal diet affect infantile colic? *The Journal of Maternal-Fetal & Neonatal Medicine* 2016;29:3139–41.
71. Lust KD, Brown JE, Thomas W. Maternal intake of cruciferous vegetables and other foods and colic symptoms in exclusively breast-fed infants. *J Am Diet Assoc* 1996;96:46–8.
72. Prospective study on the atopy preventive effect of maternal avoidance of milk and eggs during pregnancy and lactation. :5.
73. Haastrup MB, Pottegård A, Damkier P. Alcohol and Breastfeeding. *Basic Clin Pharmacol Toxicol* 2014;114:168–73.
74. Mennella JA, Pepino MY, Teff KL. Acute alcohol consumption disrupts the hormonal milieu of lactating women. *J Clin Endocrinol Metab* 2005;90:1979–85.
75. McKenna KM, Shankar RT. The Practice of Prelacteal Feeding to Newborns Among Hindu and Muslim Families. *Journal of Midwifery & Women's Health* 2009;54:78–81.
76. Patel A, Banerjee A, Kaletwad A. Factors Associated with Prelacteal Feeding and Timely Initiation of Breastfeeding in Hospital-Delivered Infants in India. *J Hum Lact* 2013;29:572–8.
77. Dórea JG. Persistent, bioaccumulative and toxic substances in fish: Human health considerations. *Science of The Total Environment* 2008;400:93–114.
78. Nutrition C for FS and A. Advice about Eating Fish. FDA [Internet] 2019 [cited 2019 Jul 26]; Available from: <http://www.fda.gov/food/consumers/advice-about-eating-fish>
79. Brown CRL, Dodds L, Legge A, Bryanton J, Semenic S. Factors influencing the reasons why mothers stop breastfeeding. *Can J Public Health* 2014;105:e179–85.

80. Hauck YL, Fenwick J, Dhaliwal SS, Butt J. A Western Australian Survey of Breastfeeding Initiation, Prevalence and Early Cessation Patterns. *Matern Child Health J* 2011;15:260–8.
81. Bergman NJ. Neonatal stomach volume and physiology suggest feeding at 1-h intervals. *Acta Paediatr* 2013;102:773–7.
82. Hondeghem LM, Logghe NH. Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child. *Drug Saf* 2017;40:109–13.
83. Brodribb W, the Academy of Breastfeeding Medicine. ABM Clinical Protocol #9: Use of Galactagogues in Initiating or Augmenting Maternal Milk Production, Second Revision 2018. *Breastfeeding Medicine* 2018;13:307–14.
84. Sewell DD. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. *Archives of Family Medicine* 1992;1:271–8.
85. Wagner CL, Boan AD, Marzolf A, Finch CW, Morella K, Guille C, Gardner Z, Marriott BP. The Safety of Mother’s Milk® Tea: Results of a Randomized Double-Blind, Controlled Study in Fully Breastfeeding Mothers and Their Infants. *J Hum Lact* 2019;35:248–60.
86. Korman SH, Cohen E, Preminger A. Pseudo-maple syrup urine disease due to maternal prenatal ingestion of fenugreek. *J Paediatr Child Health* 2001;37:403–4.
87. Sewell AC, Mosandl A, Böhles H. False diagnosis of maple syrup urine disease owing to ingestion of herbal tea. *N Engl J Med* 1999;341:769.
88. Reeder C, Legrand A, O’connor-Von SK. The Effect of Fenugreek on Milk Production and Prolactin Levels in Mothers of Preterm Infants. *Clin Lactation* 2013;4:159–65.
89. Trial Exploring the Efficacy and Safety of FE 202767 - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jul 4]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02545127>
90. Ear PH, Chadda A, Gumusoglu SB, Schmidt MS, Vogeler S, Malicoat J, Kadel J, Moore MM, Migaud ME, Stevens HE, et al. Maternal Nicotinamide Riboside Enhances Postpartum Weight Loss, Juvenile Offspring Development, and Neurogenesis of Adult Offspring. *Cell Reports* 2019;26:969-983.e4.
91. Miller MA, Mehta N, Clark-Bilodeau C, Bourjeily G. Sleep Pharmacotherapy for Common Sleep Disorders in Pregnancy and Lactation. *Chest* 2020;157:184–97.

92. Eustis EH, Ernst S, Sutton K, Battle CL. Innovations in the Treatment of Perinatal Depression: the Role of Yoga and Physical Activity Interventions During Pregnancy and Postpartum. *Curr Psychiatry Rep* 2019;21:133.
93. Dipietro L, Evenson KR, Bloodgood B, Sprow K, Troiano RP, Piercy KL, Vaux-Bjerke A, Powell KE, 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Benefits of Physical Activity during Pregnancy and Postpartum: An Umbrella Review. *Med Sci Sports Exerc* 2019;51:1292–302.
94. Christian LM, Carroll JE, Teti DM, Hall MH. Maternal Sleep in Pregnancy and Postpartum Part I: Mental, Physical, and Interpersonal Consequences. *Curr Psychiatry Rep* 2019;21:20.
95. Carroll JE, Teti DM, Hall MH, Christian LM. Maternal Sleep in Pregnancy and Postpartum Part II: Biomechanisms and Intervention Strategies. *Curr Psychiatry Rep* 2019;21:19.
96. Sheffield KM, Woods-Giscombé CL. Efficacy, Feasibility, and Acceptability of Perinatal Yoga on Women's Mental Health and Well-Being: A Systematic Literature Review. *J Holist Nurs* 2016;34:64–79.
97. Okun ML. Disturbed Sleep and Postpartum Depression. *Curr Psychiatry Rep* 2016;18:66.
98. Lovelady C. Balancing exercise and food intake with lactation to promote post-partum weight loss. *Proc Nutr Soc* 2011;70:181–4.
99. Larson-Meyer DE. Effect of postpartum exercise on mothers and their offspring: a review of the literature. *Obes Res* 2002;10:841–53.
100. Colleran HL, Wideman L, Lovelady CA. Effects of energy restriction and exercise on bone mineral density during lactation. *Med Sci Sports Exerc* 2012;44:1570–9.
101. Yu J, Wells J, Wei Z, Fewtrell M. Effects of relaxation therapy on maternal psychological state, infant growth and gut microbiome: protocol for a randomised controlled trial investigating mother-infant signalling during lactation following late preterm and early term delivery. *Int Breastfeed J* 2019;14:50.
102. McClements DJ, Li F, Xiao H. The Nutraceutical Bioavailability Classification Scheme: Classifying Nutraceuticals According to Factors Limiting their Oral Bioavailability. *Annu Rev Food Sci Technol* 2015;6:299–327.

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Preterm Infants (MOONRISE) Study: Protocol for a Double-Blind Placebo-Controlled Clinical Trial

Erin L. Ford

Introduction

Successful lactation is broadly defined as an adaptive process that is mutually supportive of mother and infant while adequately providing for infant growth and development (1). The lack of detailed knowledge about lactation has been most profoundly detrimental to premature infants and their mothers. Numerous studies indicate that these infants benefit most from consuming human milk (2–4) and yet mothers who have delivered prematurely experience greater difficulty in initiating and maintaining an adequate milk supply compared to those who have delivered at term (5,6). The rate of births that occur at or before 32 weeks of gestation is approaching 10% and continues to grow (7). Preterm infants are at an increased risk of health complications, and those that are admitted to the neonatal intensive care unit (NICU) typically receive a combination of enriched formula, donor milk, and their mother's own milk. Mounting evidence supports adequate milk production as one of the most significant determiners of health outcomes among at-risk premature infants (2,8–10).

A galactagogue refers to a class of bioactive substance that stimulates milk production. The only prescription medication approved by the FDA for use as a galactagogue in the United States is metoclopramide, which acts as a dopamine antagonist to encourage milk production by increasing levels of prolactin. Additionally, several botanical and over-the-counter supplements, including fenugreek, have been popularized as holistic alternatives despite a considerable lack of evidence of efficacy, long-term safety, and biochemical mechanism of action.

Systemic metabolism is substantially altered during postpartum and lactation as a mother's body is adapting to synthesize milk for her infant while simultaneously recovering from birthing trauma. Though low milk supply may be a consequence of combined physiological, hormonal, and environmental factors, recent evidence points to insufficient mobilization of cellular substrates as a common bottleneck in this system. Ear et al. demonstrated that, in lactating

rodents, the niacin precursor nicotinamide riboside (NR) effectively augmented milk production and promoted lean body composition in dams while also conferring neurocognitive, metabolic, and developmental advantages to their offspring (11). NR has undergone long-term safety and bioavailability studies in humans but has not yet been examined for use as a galactagogue (12–14). If this supplement does positively affect lactation efficiency, mothers of infants in the NICU are a critical population who could uniquely benefit.

The following study design includes details for a pilot study which, at the time of publication, has not started. This trial is intended to generate statistically meaningful data to resolve the hypothesis that providing nicotinamide riboside as an oral supplement supports a biologically important increase in milk production and quality in mothers of preterm infants. The primary aim is to determine whether NR influences 24-hour milk volume and, further, whether additional changes in metabolism or endocrine signaling are observed over the course of a two-week intervention period.

Methods

Study Design

The MOONRISE study is a randomized, double-blind, parallel clinical trial that lasts 17 days in total and is designed to be conducted on-site at the University of California Davis Medical Center (2315 Stockton Blvd, Sacramento, CA 95817). Prior to enrollment, each potential participant undergoes pre-screening and screening processes to determine eligibility based on select inclusion and exclusion criteria. Following these procedures, the study team conducts an initial study visit wherein subjects are provided informed consent and officially enrolled in the study. Over the next three days, participants collect their first of three 24-hour milks. At the next study visit on day 3, mothers will be stratified by parity according to whether they have previously birthed a child or not (multiparous or primiparous, respectively), then randomized to receive either an inert placebo or the study supplement for 14 days (Figure 1).




Figure 2. Procedure for recruitment, screening, and determination of study group.

Activities that participants complete throughout the trial are illustrated chronologically in Figure 2. Collection of 24-hour milk occurs on three occasions and urine on two occasions. At each study visit after day 0, a member of the study team will also collect a small sample from freshly expressed milk at the NICU. Two optional blood draws are included on days 3 and 11 for mothers who elect to participate. Mothers are randomized on day 3 at the study visit prior to beginning supplementation on day 4. Mothers continue to take the supplement until the final study visit on day 17.

Randomization

The investigational pharmacy at UCDMC will be provided with the parity status of each participant following consent. The pharmacist will then assign a unique identification number to the mother based on a randomized block design within each stratification group. All study personnel will remain blinded until primary analyses have been completed.

Study Population

Pre-screening of potential study participants is performed at the discretion of the clinical trial physician and other trained members of the NICU care team including nursing staff, lactation consultants, and student research fellows based on select inclusion and exclusion criteria. All participants must be at least 18 years of age at the time of enrollment and reside (either permanently or for the duration of the study) within 50 miles of the UC Davis Medical Center. Mothers are identified and recruited by internal staff at the UC Davis Medical Center. Any mother who delivers a live infant at or before 32 weeks gestation is provided with informational materials about the study and instructed to contact the study coordinator if interested. Selection of final eligibility is determined in a more comprehensive screening process conducted by phone interview. Those who meet all selection criteria and who are still interested in participating are scheduled for an enrollment visit and sent an electronic form of the consent form to preview.




Figure 3. Activities timeline for the 17-day duration of the MOONRISE study. Symbols represent events denoted in the figure legend.

Inclusion/Exclusion Criteria

All participants must meet all requirements at the time of enrollment. The study coordinator reserves the right to exclude anyone deemed not fit for participation in this study.

Inclusion Criteria

- Infants delivered at or before 32 weeks gestation
- Infants born at the UC Davis Medical Center or transferred within the first 7 days of life
- Mothers 18 years or older
- Mothers with singleton pregnancies
- Mothers who have delivered at least 96 hours prior to the enrollment visit
- Mothers who attempt initial milk expression within 12 hours of delivery
- Mothers who have attempted milk expression at least 6 times in a 24-hour period from 72 hours after delivery to the enrollment visit
- Mothers who plan to feed their infant breast milk for at least 3 months

- Mothers who have experience onset of lactogenesis II before beginning collection of their first 24-hour milk
- Mothers willing to refrain from tandem feeding another child during the study
- Mothers who are willing to refrain from enrolling themselves or their infant in another intervention trial during the study
- Mothers willing to express, collect, and record 24-hour milk
- Mothers willing to remove nipple piercings during the study
- Mothers willing to refrain from using products containing pseudoephedrine during the study
- Mothers willing to express milk 8 or more times in a 24-hour period, including at least once during the night
- Mothers willing to refrain from consuming non-study supplements that contain nicotinamide riboside or similar derivatives during the study
- Mothers willing to refrain from consuming galactagogues during the study

Exclusion Criteria

- Infants postnatal age greater than 8 days
- Infants participating in another intervention trial
- Mothers who were pregnant with multiples
- Mothers who are participating in another intervention trial
- Mothers who are currently tandem feeding another child
- Mothers who have previously undergone breast surgery or have experienced other breast trauma
- Mothers using medications or recreational drugs that contraindicate breastfeeding
- Mothers who are undergoing cancer treatment
- Mothers who are receiving lithium or gold therapies
- Mothers planning to use over-the-counter or prescription medication for the purpose of increasing milk supply during the study
- Mothers who are taking hormonal birth control or are planning to resume use of hormonal birth control during the study

- Mothers who are involuntarily confined
- Mothers who are unable to consent
- Mothers residing greater than 50 miles away while their infant is receiving care at UCDCM
- Mothers who have taken a supplement containing nicotinamide riboside or similar derivatives within the past 9 months

Study Supplement

Niagen® nicotinamide riboside chloride 250 mg capsule, marketed as Tru Niagen® and produced by Chromadex, Inc., was selected because of its demonstrated galactagogic effects in rodents and its efficacy in humans for increasing circulating NAD⁺ without adverse effects associated with long-term use. NR was produced from D-ribofuranose tetraacetate in accordance with cGMP at a certified contract manufacturing organization. The product of a two-step synthesis was vacuum-dried, milled, sieved, and passed through a magnet to yield nicotinamide-D-ribose chloride. Structural determination was achieved by means of NMR and mass spectral analysis (15).

The UCDCM investigational pharmacy is responsible for randomization. Both the supplement and placebo are dispensed as opaque capsules in 14-count bottles. Compliance is assessed at the final study visit, when participants are asked to bring the supplement bottle with them, where any remaining pills are counted and recorded by study personnel. Daily intake logs provide a secondary means of verifying compliance.

Questionnaires

Participants complete four questionnaires throughout the study. An initial health questionnaire is designed to assess lifestyle and health history. A pregnancy and reproduction questionnaire—also completed at the enrollment visit—will obtain information about the mother's reproductive history and her most recent pregnancy. Additionally, an onset of milk production questionnaire aims approximate lactogenesis II, as indicated by a transition from colostrum to mature milk and a significant increase in milk volume produced. Mothers are asked to rate their perceived breast fullness on a scale from 1 to 5 each day following their baby's birth until a '3' is reported (Figure 3). This information will be used to determine when colostrum is no longer being produced and 24-hour milk can begin to be collected.

Finally, an end-of-study questionnaire, completed at the final study visit, asks about mothers' experiences in participating in the trial.

Day 1 (<i>day of your baby's birth</i>)	Baby's birth date: _____ Baby's birth time: _____
<p>1. Please rate your breast fullness, on a scale from 1 to 5, on the date of your baby's birth date compared to before giving birth.</p> <p><i>[1 = no change, 3 = noticeably fuller, and 5 = uncomfortably full]</i></p> <p>[circle only 1 answer]</p>	<p>1 2 3 4 5</p>
<p>2. If you rated 3 or higher for question #1, approximately what date and time did you experience this change?</p>	<p>Date: _____ Time: _____</p> <p><input type="checkbox"/> Did not rate 3 or higher</p>

Figure 4. Onset of milk production sample entry form.

Daily and Weekly Logs

From day 1 until day 17, participants are asked to complete daily lactation and interaction logs, which ask mothers to report the frequency of milk expression as well as any skin-to-skin or virtual contact with their baby. Additionally, daily intake logs prompt mothers to record study supplement and non-study supplement intake as well as alcohol consumption. A member of the study team will check these logs for completeness at each study visit to determine compliance.

Participants also complete two weekly logs during the study period. These are designed to monitor factors known to influence milk supply including return of menses, use of contraception, use of cannabis or nicotine-containing products, changes in breast health, and use of lactation support resources.

Sample Collection

24-Hour Milk Volume

Participants are provided with a Medela Symphony PLUS® dual electric breast pump for use throughout the study. A certified lactation consultant will assist in fitting each mother with the correct size breast flange prior to the first 24-

hour milk collection. All mothers are instructed to pump on the *MAINTAIN* program every 2-3 hours for at least 15 minutes, using the hands-on pumping technique (i.e., massaging and compressing of breasts before and throughout pumping session). Two minutes of hand expression of milk is encouraged at the end of each pumping session to facilitate complete milk removal. Pre-labeled 120 mL bottle are provided for milk collection. Mothers are asked to complete a 24-hour milk collection and recording log to keep track of sessions over the course of a 24-hour period. Two protocols have been developed, differing only in the frequency of sample drop-offs at the NICU. This modification was implemented to accommodate participants who need to bring their milk to the hospital with greater frequency to feed their infant during 24-hour milk collection. According to protocol 1, all 120 mL bottles are kept in the participant's home refrigerator until transport on ice to the study visit the following day. For protocol 2, 120 mL from one or more pumping sessions are transported in piecewise fashion to the NICU and delivered to a member of the study team. All milk from 24-hour collections will be kept refrigerated and used to supplement the infant's diet while in the NICU. Quantitative data collected from the 24-hour milk collection and recording log will be used to determine total 24-hour volumes.

Expressed Milk Sample

A 7 mL sample is collected from pooled, freshly expressed milk on three occasions. Aliquots will be stored in a sample freezer in the NICU at -40°C for the remainder of the trial, then transported on dry ice to a -80°C freezer located at the UC Davis Robert Mondavi Institute (392 Old Davis Rd, Davis, CA 95616) until analysis. Macronutrient compositional analysis of milk samples will be performed using the MIRIS HMA™ and will be run in duplicate.

Maternal Urine

Midstream urine is collected using a BD Vacutainer® urine collection kit (Thermo Fisher Scientific, Houston TX), which is equipped with an integrated transfer system and 10.0 mL sterile polyethylene tubes. Samples are stored in the participant's home freezer (approximately -18°C) and transferred on ice to UCDCM for each study visit. All urine samples will remain at -80°C until transported in batches on dry ice to a -80°C freezer located at the UC Davis Robert Mondavi Institute (392 Old Davis Rd, Davis, CA 95616) until analysis. Comparison of urinary metabolites between

treatments will be conducted according to established protocols used for previous studies by our research team. Samples of urine will be run in duplicate.

Serum Prolactin

At enrollment, mothers are presented with the option to consent to two blood draws during the study for measurement of serum prolactin, which is directly related to milk production. Five phlebotomy centers on the UC Davis Medical Center campus will provide these services free of charge to subjects enrolled in the MOONRISE study. On days 3 and 11, participants are asked to have blood drawn before 11 a.m. to control for diurnal fluctuations in prolactin levels. All analyses will be performed by the UCDCMC pathology laboratory in accordance with standard protocol.

Power Analysis

It is unlikely that the anticipated sample size will be sufficiently powered to detect differences in the primary outcome measure; rather, this study will generate variance for the variables of interest. The number of mother-infant dyads was chosen based on feasibility of enrollment within a proposed time period. We aim to enroll 48 mother-infant pairs with the expectation that 44 will complete the study ($n = 22$ in each group). This is based on a recent meta-analysis conducted by Taylor et al. (16), which reported on the use of a galactagogue domperidone on 24-hour milk volume in several studies. Standard deviation (SD) is assumed to be 120 g/d for human milk, with a difference in volume between groups of 100 g/d. Using a power of 80% and a significance level of 0.05 with two study groups, the required sample size (n) was calculated using the following equation: $n = 2 \times 7.85 (SD/difference\ of\ the\ means)^2$, where 7.85 is the multiplication factor $f(\alpha, power)$.

Statistical Analysis

The primary outcome is mean 24-hour milk volume following 14 days of supplementation. We will analyze these data using either two sample t-tests or non-parametric Mann Whitney U, depending on the distribution of final data. Secondary outcomes include protein, carbohydrate, and fat content of individual milk samples that have been collected from a single breast, which will be compared using two sample t-tests.

Data and Specimen Banking

Samples will be stored in a locked -80°C freezer under supervision by the study coordinator at the UC Davis Robert Mondavi Institute (392 Old Davis Rd, Davis, CA 95616) until the remaining samples from all participants have been received. Data and/or specimens will be kept for a maximum of 10 years after completion of the study and then destroyed. Completion of CITI training modules is required of all personnel involved in data and/or specimen collection. Both clinical and sample analysis data are recorded in electronic spreadsheets, which are maintained on secure servers that contain no patient identifiers. Following completion of the study and sample analyses, study personnel will be unblinded and results will be linked back to patient identifiers. Group assignments will be revealed by the investigational pharmacy to allow for data analysis.

Discussion and Conclusion

This study is designed to examine whether NR supplementation affects 24-hour milk volume outcomes, and additionally, to acquire evidence via secondary outcome measures in support of the mechanistic hypothesis that lactation performance is related to NAD metabolism. The increase in preterm birth is occurring in parallel with an epidemic of subthreshold metabolic syndromes that are exacerbated by pregnancy. It is also now well-established that a history of gestational diabetes correlates strongly with non-alcoholic fatty liver disease later in life (17). The liver functions as a central site of active metabolism during lactation and is essential for coordinated milk synthesis and excretion from the mammary epithelia. The consequences of hepatic dysfunction in mothers highlight the need for more targeted interventions. Further, by presenting lactation within its rightful context as a priority of long-term public health we intend to fuel legitimate conversations among researchers and policymakers.

In rodent models, it is posited that oral NR increases milk production by means of superinduced fuel mobilization and turnover within the NAD⁺ metabolome in dams (11). NAD⁺ is implicated in all energy-dependent metabolism. Lactation itself is a massively costly process predicated on effective mobilization of existing NAD⁺ stores, recruitment of substrates for *de novo* synthesis, and accessibility of diet-derived bioactive compounds required for homeorhetic processes during early postpartum. In redox reactions, NAD⁺ serves as a coenzyme for the reversible conversion to and from NADH. NAD⁺ also functions as a co-substrate in signaling pathways involving ADP-ribose transferases

(ARTs) and poly(ADP-ribose) transferases (PARPs); cyclic ADP-ribose (cADPR) synthases, and sirtuins (SIRTs). These reactions result in cleavage of NAD⁺ to nicotinamide and ADP-ribosyl (18). Nicotinamide riboside acts as one of four primary extracellular precursors of NAD⁺. Most dietary precursors are not readily taken up and are in many cases limited in their ability to be enzymatically converted to NAD⁺. Recent studies have illuminated the clinical potential for an alternative path via NR, which appears to be the mitochondria-preferred NAD⁺ precursor (13,19–21). This raises the fundamental question: can NR alleviate the increased maternal demands of lactation?

If this pilot study generates data to support that supplementing mothers of preterm infants with NR results in increased milk synthesis, then such an outcome would inform a path to the use of mechanism-defined galactagogues capable of supporting lactation in all mothers. If the data do not indicate any statistically significant difference in milk volume or composition, then it is possible that humans and rodents fundamentally differ in their regulation of milk synthesis; thus, interventions will need to target systemic metabolism through alternative pathways. Effects may also be confounded by aspects of the study design including supplement dosage, duration of the intervention, or additional physiological factors. Nonetheless, both positive and negative outcomes are valuable and demonstrate the potential to guide future research in lactation.

References

1. Boss M, Gardner H, Hartmann P. Normal Human Lactation: closing the gap. *F1000Res* 2018;7.
2. Underwood MA. Human Milk for the Premature Infant. *Pediatric Clinics of North America* 2013;60:189–207.
3. Tudehope DI. Human Milk and the Nutritional Needs of Preterm Infants. *The Journal of Pediatrics* 2013;162:S17–25.
4. Brown JVE, Lin L, Embleton ND, Harding JE, McGuire W. Multi-nutrient fortification of human milk for preterm infants. Cochrane Neonatal Group, editor. *Cochrane Database of Systematic Reviews* [Internet] 2020 [cited 2020 Sep 29]; Available from: <http://doi.wiley.com/10.1002/14651858.CD000343.pub4>
5. Hill PD, Aldag JC, Chatterton RT, Zinaman M. Comparison of Milk Output Between Mothers of Preterm and Term Infants: The First 6 Weeks After Birth. *J Hum Lact* 2005;21:22–30.
6. Hackman NM, Schaefer EW, Beiler JS, Rose CM, Paul IM. Breastfeeding Outcome Comparison by Parity. *Breastfeeding Medicine* 2015;10:156–62.
7. National Vital Statistics Reports Volume 67, Number 1, January 31, 2018. 67:55.
8. Lewis ED, Richard C, Larsen BM, Field CJ. The Importance of Human Milk for Immunity in Preterm Infants. *Clinics in Perinatology* 2017;44:23–47.
9. Menon G, Williams TC. Human milk for preterm infants: why, what, when and how?: Table 1. *Arch Dis Child Fetal Neonatal Ed* 2013;98:F559–62.
10. Meier PP, Johnson TJ, Patel AL, Rossman B. Evidence-Based Methods That Promote Human Milk Feeding of Preterm Infants: An Expert Review. *Clin Perinatol* 2017;44:1–22.
11. Ear PH, Chadda A, Gumusoglu SB, Schmidt MS, Vogeler S, Malicoat J, Kadel J, Moore MM, Migaud ME, Stevens HE, et al. Maternal Nicotinamide Riboside Enhances Postpartum Weight Loss, Juvenile Offspring Development, and Neurogenesis of Adult Offspring. *Cell Reports* 2019;26:969-983.e4.
12. Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide

riboside (NR) and its effects on blood NAD⁺ levels in healthy volunteers. Sinclair DA, editor. PLoS ONE 2017;12:e0186459.

13. Bogan KL, Brenner C. Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD⁺ Precursor Vitamins in Human Nutrition. *Annual Review of Nutrition* 2008;28:115–30.

14. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. *Sci Rep* 2019;9:9772.

15. Agency Response Letter GRAS Notice No. GRN 000635 [Internet]. 2016. Available from: <https://www.fda.gov/food/gras-notice-inventory/agency-response-letter-gras-notice-no-grn-000635>

16. Taylor A, Logan G, Twells L, Newhook LA. Human Milk Expression After Domperidone Treatment in Postpartum Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Hum Lact* 2019;35:501–9.

17. Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease: *American Journal of Gastroenterology* 2016;111:658–64.

18. Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. *Science* 2015;350:1208–13.

19. Trammell SAJ, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. *Nature Communications* 2016;7:12948.

20. Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, et al. The NAD⁺ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity. *Cell Metabolism* 2012;15:838–47.

21. She J, Sheng R, Qin Z-H. Pharmacology and Potential Implications of Nicotinamide Adenine Dinucleotide Precursors. *Aging Dis* 2021;12:1879–97.